Consorcio Centro de Investigación Biomédica en Red (CIBER)
Quick facts
Phase 3 pipeline
- Esmolol Injection [Brevibloc] · Cardiovascular
Esmolol is a selective beta-1 adrenergic receptor antagonist that rapidly blocks sympathetic stimulation of the heart, reducing heart rate and blood pressure.
Competitive intelligence
For the full portfolio CI brief — phase mix, recent regulatory actions, upcoming PDUFA dates, patent timeline, class-overlap with competitors:
- Consorcio Centro de Investigación Biomédica en Red (CIBER) portfolio CI brief
- Consorcio Centro de Investigación Biomédica en Red (CIBER) pipeline updates RSS
Frequently asked questions about Consorcio Centro de Investigación Biomédica en Red (CIBER)
What is Consorcio Centro de Investigación Biomédica en Red (CIBER)'s pipeline?
Consorcio Centro de Investigación Biomédica en Red (CIBER) has 1 drugs in Phase 3, 0 in Phase 2, 0 in Phase 1. Late-stage candidates include Esmolol Injection [Brevibloc].
Related
- Sector hub: All tracked pharma companies